Antibacterial/JJ
and/CC
Pharmacological/JJ
Evaluation/NN
of/IN
Fluoroquinolones/NNS
:/:
A/DT
Chemoinformatics/NNS
Approach/NN
./.
====================
Fluoroquinolone/NN
(/(
FQ/NN
)/)
antibiotics/NNS
are/VBP
an/DT
important/JJ
class/NN
of/IN
synthetic/JJ
antibacterial/JJ
agents/NNS
./.
====================
These/DT
are/VBP
the/DT
most/JJS
extensively/RB
used/VBN
drugs/NNS
for/IN
treating/VBG
bacterial/JJ
infections/NNS
in/IN
the/DT
field/NN
of/IN
both/DT
human/JJ
and/CC
veterinary/JJ
medicine/NN
./.
====================
Herein/RB
,/,
the/DT
antibacterial/JJ
and/CC
pharmacological/JJ
properties/NNS
of/IN
four/CD
fluoroquinolones/NNS
:/:
lomefloxacin/NN
,/,
norfloxacin/NN
,/,
ciprofloxacin/NN
,/,
and/CC
ofloxacin/NN
have/VBP
been/VBN
studied/VBN
./.
====================
The/DT
objective/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
analyze/VB
the/DT
antibacterial/JJ
characteristics/NNS
of/IN
the/DT
different/JJ
fluoroquinolones/NNS
./.
====================
Also/RB
,/,
the/DT
pharmacological/JJ
properties/NNS
of/IN
the/DT
compounds/NNS
including/VBG
the/DT
Lipinski/NN
rule/JJ
of/IN
five/CD
,/,
absorption/NN
,/,
distribution/NN
,/,
metabolism/NN
,/,
and/CC
excretion/NN
,/,
LD50/NN
,/,
drug/NN
likeliness/NN
,/,
and/CC
toxicity/NN
were/VBD
evaluated/VBN
./.
====================
We/PRP
found/VBD
that/IN
among/IN
all/DT
four/CD
FQ/NN
molecules/NNS
,/,
ofloxacin/IN
showed/VBD
the/DT
highest/JJS
antibacterial/JJ
activity/NN
through/IN
in/IN
silico/NN
assays/NNS
with/IN
a/DT
strong/JJ
interaction/NN
(/(
−38.52/CD
kJ/mol/NN
)/)
with/IN
the/DT
antibacterial/JJ
target/NN
protein/NN
(/(
topoisomerase-II/NN
DNA/NN
gyrase/NN
enzyme/NN
)/)
./.
====================
The/DT
pharmacological/JJ
and/CC
pharmacokinetic/JJ
analysis/NN
also/RB
showed/VBD
that/IN
the/DT
compounds/NNS
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
have/VBP
good/VBN
pharmacological/JJ
properties/NNS
./.
====================
Notably/RB
,/,
ofloxacin/NN
was/VBD
found/VBN
to/TO
possess/VB
an/DT
IGC50/NN
(/(
concentration/NN
needed/VBD
to/TO
inhibit/VB
50/CD
%/NN
growth/NN
)/)
value/NN
of/IN
0.286/CD
μg/L/NN
against/IN
the/DT
Tetrahymena/NN
pyriformis/NN
protozoa/NN
./.
====================
It/PRP
also/RB
tested/VBN
negative/JJ
for/IN
the/DT
Ames/NNS
toxicity/NN
test/NN
,/,
showing/VBG
its/PRP$
non-carcinogenic/JJ
character/NN
./.
====================
Fluoroquinolones/NNS
(/(
FQs/NNS
)/)
are/VBP
one/CD
of/IN
the/DT
most/JJS
extensively/RB
used/VBN
antibiotics/NNS
in/IN
human/JJ
therapy/NN
and/CC
veterinary/JJ
treatment/NN
[/(
1/CD
]/)
./.
====================
These/DT
compounds/NNS
are/VBP
of/IN
exceptional/JJ
interest/NN
because/IN
their/PRP$
clinical/JJ
role/NN
has/VBZ
vastly/RB
expanded/VBN
since/IN
the/DT
introduction/NN
of/IN
norfloxacin/NN
in/IN
the/DT
1980s/NN
[/(
2/CD
]/)
./.
====================
The/DT
antibacterial/JJ
activity/NN
of/IN
FQs/JJ
results/NNS
from/IN
their/PRP$
inhibition/NN
of/IN
different/JJ
kinds/NNS
of/IN
enzymes/NNS
,/,
such/JJ
as/IN
type/NN
II/CD
topoisomerase/NN
,/,
DNA/NN
gyrase/NN
and/CC
DNA/NN
topoisomerase/NN
IV/CD
,/,
which/WDT
control/VBP
DNA/NN
topology/NN
and/CC
are/VBP
vital/JJ
for/IN
chromosome/NN
replication/NN
and/CC
function/NN
[/(
3/CD
]/)
./.
====================
Structural/JJ
modifications/NNS
to/TO
the/DT
key/JJ
building/VBG
block/VBP
element/NN
of/IN
quinolone/RB
have/VBP
led/VBN
to/TO
an/DT
expanded/VBN
antibacterial/JJ
activity/NN
,/,
optimal/JJ
pharmacokinetics/NNS
,/,
and/CC
a/DT
better/RBR
safety/NN
profile/NN
[/(
4/CD
]/)
./.
====================
There/EX
are/VBP
currently/RB
four/CD
generations/NNS
of/IN
FQs/JJ
and/CC
the/DT
first-generation/JJ
drugs/NNS
or/CC
the/DT
original/JJ
quinolones/NNS
were/VBD
not/RB
fluorinated/VBN
and/CC
included/VBD
drugs/NNS
like/IN
oxolinic/JJ
acid/NN
and/CC
nalidixic/JJ
acid/NN
./.
====================
The/DT
next/JJ
generation/NN
,/,
which/WDT
included/VBD
fluorinated/JJ
compounds/NNS
exhibited/VBD
enhanced/VBN
antimicrobial/JJ
activity/NN
against/IN
gram-negative/JJ
bacteria/NNS
and/CC
extended/VBD
their/PRP$
activity/NN
to/TO
some/DT
gram-positive/JJ
bacteria/NNS
./.
====================
These/DT
compounds/NNS
are/VBP
classified/VBN
as/IN
second-generation/NN
FQs/NNS
and/CC
include/VBP
drugs/NNS
such/JJ
as/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
./.
====================
An/DT
expanded/VBN
activity/NN
against/IN
gram-positive/JJ
bacteria/NNS
,/,
while/IN
retaining/VBG
broad/JJ
gram-negative/JJ
coverage/NN
was/VBD
exhibited/VBD
by/IN
the/DT
third/JJ
generation/NN
FQs/NNS
,/,
which/WDT
included/VBD
levofloxacin/NN
./.
====================
Lastly/RB
,/,
the/DT
fourth/JJ
generation/NN
FQs/NNS
,/,
such/JJ
as/IN
clinafloxacin/NN
,/,
inhibited/VBD
anaerobic/JJ
bacteria/NNS
,/,
while/IN
retaining/VBG
the/DT
gram-positive/JJ
and/CC
gram-negative/JJ
antibacterial/JJ
activity/NN
[/(
5/CD
,/,
6/CD
]/)
./.
====================
The/DT
four/CD
FQs/NNS
in/IN
this/DT
study/NN
(/(
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
)/)
belong/VBP
to/TO
the/DT
class/NN
of/IN
second-generation/NN
FQs/NNS
./.
====================
Ciprofloxacin/NN
is/VBZ
an/DT
antibiotic/JJ
that/DT
is/VBZ
widely/RB
used/VBN
for/IN
the/DT
treatment/NN
of/IN
bacterial/JJ
infection/NN
[/(
7/CD
]/)
./.
====================
This/DT
includes/VBZ
skin/NN
infections/NNS
,/,
bone/NN
and/CC
joint/NN
infections/NNS
and/CC
urinary/JJ
tract/NN
infections/NNS
,/,
among/IN
others/NNS
[/(
8/CD
]/)
./.
====================
Ciprofloxacin/NN
is/VBZ
on/IN
the/DT
World/NN
Health/NN
Organization/NN
’/CD
s/NNS
(/(
WHO/NN
)/)
“/CD
List/NN
of/IN
Essential/JJ
Medicines/NNS
”/CD
[/(
9/CD
]/)
./.
====================
Lomefloxacin/NN
is/VBZ
a/DT
difluorinated/JJ
quinolone/RB
used/VBN
to/TO
treat/VB
bacterial/JJ
infections/NNS
including/VBG
respiratory/JJ
and/CC
urinary/JJ
tract/NN
infections/NNS
,/,
and/CC
skin/NN
,/,
eye/NN
,/,
throat/IN
infections/NNS
[/(
10/CD
]/)
./.
====================
Ofloxacin/NN
is/VBZ
useful/JJ
for/IN
treating/VBG
bacterial/JJ
infections/NNS
of/IN
eye/JJ
,/,
ear/JJ
[/(
11/CD
]/)
,/,
prostatitis/NN
[/(
12/CD
]/)
,/,
and/CC
certain/JJ
types/NNS
of/IN
infectious/JJ
diarrhea/NN
[/(
13/CD
]/)
./.
====================
Norfloxacin/NN
is/VBZ
used/VBN
to/TO
treat/VB
urinary/JJ
tract/NN
infections/NNS
,/,
gonorrhea/NN
and/CC
bladder/JJ
and/CC
gynecological/JJ
infections/NNS
[/(
14/CD
]/)
./.
====================
In/IN
this/DT
work/NN
,/,
our/PRP$
interest/NN
is/VBZ
to/TO
study/VB
the/DT
antibacterial/JJ
activity/NN
of/IN
FQs/NN
by/IN
molecular/JJ
docking/NN
assays/NNS
./.
====================
We/PRP
studied/VBD
the/DT
inhibiting/VBG
activity/NN
of/IN
the/DT
selected/VBN
compounds/NNS
with/IN
an/DT
antibacterial/JJ
target/NN
protein/NN
./.
====================
Furthermore/RB
,/,
pharmacological/JJ
studies/NNS
of/IN
the/DT
compounds/NNS
were/VBD
performed/VBN
./.
====================
DNA/NN
gyrase/NN
has/VBZ
extensively/RB
been/VBN
investigated/VBN
as/IN
a/DT
target/NN
to/TO
study/VB
the/DT
mechanism/NN
of/IN
action/NN
for/IN
antibacterial/JJ
compounds/NNS
./.
====================
FQs/NNS
arrest/NN
the/DT
gyrase/NN
reaction/NN
after/IN
DNA/NN
cleavage/NN
leading/VBG
to/TO
the/DT
generation/NN
of/IN
double-strand/JJ
breaks/NNS
[/(
15/CD
]/)
./.
====================
To/TO
understand/VB
the/DT
interactions/NNS
of/IN
the/DT
selected/VBN
compounds/NNS
at/IN
the/DT
active/JJ
protein/NN
receptor/NN
sites/NNS
(/(
topoisomerase/NN
II/CD
DNA/NN
gyrase/NN
enzymes/NNS
)/)
,/,
docking/NN
studies/NNS
were/VBD
performed/VBN
./.
====================
Molecular/JJ
docking/NN
provides/VBZ
a/DT
rational/JJ
new/JJ
approach/NN
to/TO
study/VB
the/DT
antibacterial/JJ
properties/NNS
of/IN
drugs/NNS
[/(
16/CD
]/)
./.
====================
A/DT
pharmacological/JJ
analysis/NN
was/VBD
also/RB
done/VBN
for/IN
the/DT
second/JJ
generation/NN
FQs/NNS
[/(
17/CD
]/)
./.
====================
This/DT
analysis/NN
included/VBD
the/DT
evaluation/NN
of/IN
the/DT
pharmacological/JJ
properties/NNS
based/VBN
on/IN
Lipinski/NN
’/CD
s/NNS
rule/NN
of/IN
five/CD
,/,
drug-likeness/RB
,/,
bioactivity/NN
,/,
and/CC
the/DT
drug/NN
score/RB
[/(
18/CD
]/)
./.
====================
Furthermore/RB
,/,
in/IN
silico/NN
preclinical/JJ
trials/NNS
including/VBG
absorption/NN
,/,
distribution/NN
,/,
metabolism/NN
,/,
excretion/NN
,/,
and/CC
toxicity/NN
(/(
ADMET/NN
)/)
test/VBP
,/,
health/NN
effect/NN
probability/NN
,/,
and/CC
maximum/JJ
recommended/VBN
daily/RB
dose/NN
(/(
MRDD/NN
)/)
were/VBD
also/RB
predicted/VBN
./.
====================
Antibacterial/JJ
target/NN
protein/NN
retrieval/NN
and/CC
structural/JJ
assessment/NN
====================
Topoisomerase/NN
II/CD
DNA/NN
gyrase/NN
is/VBZ
a/DT
well-known/JJ
target/NN
protein/NN
for/IN
antibacterial/JJ
studies/NNS
,/,
as/IN
also/RB
discussed/VBN
in/IN
the/DT
introduction/NN
section/NN
above/JJ
./.
====================
The/DT
3D/NN
structure/NN
of/IN
the/DT
topoisomerase/NN
II/CD
DNA/NN
gyrase/NN
enzyme/NN
(/(
PDB/NN
ID/NN
:/:
2XCT/NN
)/)
was/VBD
downloaded/VBN
from/IN
the/DT
Protein/NN
Data/NNS
Bank/NN
[/(
19/CD
]/)
and/CC
imported/VBD
and/CC
prepared/VBN
by/IN
a/DT
multistep/JJ
process/NN
using/VBG
the/DT
protein/NN
preparation/NN
wizard/IN
of/IN
the/DT
WHATIF/NN
server/RB
[/(
20/CD
]/)
./.
====================
The/DT
protocol/NN
was/VBD
used/VBN
to/TO
obtain/VB
the/DT
optimized/VBN
and/CC
minimized/VBD
energy/NN
conformation/NN
of/IN
the/DT
target/NN
protein/NN
./.
====================
The/DT
DNA/NN
gyrase/NN
structure/NN
was/VBD
extracted/VBN
from/IN
its/PRP$
complex/NN
form/VBP
./.
====================
Following/VBG
the/DT
extraction/NN
of/IN
the/DT
structure/NN
,/,
it/PRP
was/VBD
subjected/VBN
to/TO
energy/NN
minimization/NN
using/VBG
the/DT
implementation/NN
of/IN
the/DT
optimized/VBN
potential/JJ
for/IN
liquid/JJ
simulation/NN
(/(
OPLS-2005/CD
)/)
force/VBP
field/NN
with/IN
implicit/NN
solvation/NN
./.
====================
After/IN
that/DT
,/,
the/DT
DNA/NN
gyrase/NN
structure/NN
was/VBD
assessed/VBN
by/IN
Ramachandran/NN
plot/NN
[/(
21/CD
]/)
and/CC
Verify3D/NNP
[/(
22/CD
]/)
./.
====================
Preparation/NN
of/IN
DNA/NN
gyrase/NN
protein/NN
structure/NN
for/IN
molecular/JJ
docking/NN
====================
Prior/JJ
to/TO
molecular/JJ
docking/NN
,/,
the/DT
topoisomerase/NN
II/CD
DNA/NN
gyrase/NN
protein/NN
was/VBD
prepared/VBN
to/TO
remove/VB
water/NN
molecules/NNS
and/CC
unwanted/JJ
ligands/NNS
./.
====================
All/DT
water/NN
molecules/NNS
and/CC
small/JJ
ions/NNS
except/IN
the/DT
zinc/NN
ions/NNS
were/VBD
removed/VBN
using/VBG
the/DT
protein/NN
preparation/NN
wizard/IN
on/IN
the/DT
WHATIF/NN
web/NN
interface/NN
./.
====================
Subsequently/RB
,/,
hydrogen/NN
atoms/NNS
were/VBD
added/VBN
to/TO
the/DT
structure/NN
to/TO
correct/VB
the/DT
tautomeric/JJ
and/CC
oxidation/NN
states/NNS
of/IN
amino/NN
acids/NNS
residues/NNS
./.
====================
Preparation/NN
of/IN
FQs/NN
compounds/NNS
====================
The/DT
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
compounds/NNS
were/VBD
prepared/VBN
using/VBG
the/DT
ChemDraw/NN
workspace/NN
and/CC
saved/JJ
in/IN
a/DT
requisite/JJ
format/IN
for/IN
the/DT
in/FW
silico/NN
assays/NNS
./.
====================
Ligands/NNS
were/VBD
used/VBN
for/IN
the/DT
2D/NN
to/TO
3D/NN
conversion/NN
of/IN
compounds/NNS
while/IN
the/DT
optimized/VBN
potential/JJ
for/IN
liquid/JJ
simulation/NN
force/VBP
field/NN
was/VBD
used/VBN
for/IN
conformation/NN
analysis/NN
./.
====================
The/DT
ligands/NNS
were/VBD
prepared/VBN
for/IN
molecular/JJ
docking/NN
using/VBG
the/DT
Swiss/NN
molecule/NN
preparation/NN
server/RB
./.
====================
Molecular/JJ
docking/NN
studies/NNS
====================
Molecular/JJ
docking/NN
is/VBZ
an/DT
important/JJ
computational/JJ
technique/NN
in/IN
structural/JJ
biology/NN
and/CC
computer-aided/VBD
drug/NN
design/NN
./.
====================
The/DT
major/JJ
objective/NN
of/IN
molecular/JJ
docking/NN
is/VBZ
to/TO
evaluate/VB
the/DT
feasible/JJ
binding/NN
geometries/NNS
of/IN
a/DT
putative/JJ
FQ/NN
compounds/NNS
with/IN
a/DT
target/NN
protein/NN
(/(
known/VBN
three-dimensional/JJ
structure/NN
)/)
./.
====================
To/TO
study/VB
the/DT
molecular/JJ
interaction/NN
of/IN
FQ/NN
compounds/NNS
with/IN
the/DT
topoisomerase/NN
II/CD
DNA/NN
gyrase/NN
enzymes/NNS
,/,
the/DT
crystal/JJ
structure/NN
of/IN
topoisomerase/NN
II/CD
was/VBD
downloaded/VBN
from/IN
the/DT
protein/NN
data/NNS
bank/NN
and/CC
molecular/JJ
docking/NN
studies/NNS
were/VBD
performed/VBN
using/VBG
the/DT
HEX/NN
8.0/CD
program/NN
[/(
23/CD
]/)
./.
====================
The/DT
HEX/NN
8.0/CD
CUDA/NN
program/NN
works/VBZ
by/IN
interacting/VBG
complex/NN
simulations/NNS
of/IN
steric/JJ
shape/VBP
conformation/NN
and/CC
the/DT
charge/NN
density/NN
of/IN
the/DT
structure/NN
./.
====================
The/DT
binding/NN
residues/NNS
and/CC
different/JJ
bonds/NNS
involved/VBN
in/IN
the/DT
interaction/NN
of/IN
the/DT
resulting/VBG
docked/VBD
complexes/NNS
were/VBD
evaluated/VBN
using/VBG
the/DT
chimera/NN
molecular/JJ
modeling/VBG
package/NN
and/CC
the/DT
further/JJ
docked/VBD
complexes/NNS
were/VBD
visualized/VBN
and/CC
analyzed/VBD
using/VBG
chimera/NN
[/(
24/CD
]/)
./.
====================
Pharmacological/JJ
analysis/NN
====================
The/DT
pharmacological/JJ
properties/NNS
and/CC
bioactivities/NNS
of/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
were/VBD
determined/VBN
using/VBG
various/JJ
pharmacological/JJ
methods/NNS
./.
====================
Pharmacological/JJ
properties/NNS
including/VBG
the/DT
test/NN
based/VBN
on/IN
Lipinski/NN
’/CD
s/NNS
rule/NN
of/IN
five/CD
[/(
25/CD
]/)
,/,
bioactivity/NN
,/,
drug/NN
likeliness/NN
,/,
Ames/NNS
toxicity/NN
,/,
and/CC
the/DT
antibacterial/JJ
properties/NNS
were/VBD
studied/VBN
./.
====================
Moreover/RB
,/,
the/DT
ADMET/NN
test/NN
,/,
the/DT
MRDD/NN
and/CC
other/JJ
analyses/NNS
were/VBD
also/RB
studied/VBD
using/VBG
in/IN
silico/JJ
assays/NNS
with/IN
a/DT
variety/NN
of/IN
softwares/NNS
such/JJ
as/IN
SwissADME/JJ
[/(
26/CD
]/)
,/,
ACD/I-Lab/NN
[/(
27/CD
]/)
,/,
Molinspiration/NN
,/,
and/CC
FAF/NN
Drugs/NNS
[/(
28/CD
]/)
./.
====================
Antibacterial/JJ
DNA/NN
gyrase/NN
of/IN
Staphylococcus/FW
aureus/FW
retrieval/JJ
====================
The/DT
three-dimensional/JJ
structure/NN
of/IN
topoisomerase-II/NN
DNA/NN
gyrase/NN
enzyme/NN
of/IN
Staphylococcus/FW
aureus/FW
bacteria/NNS
origin/NN
was/VBD
retrieved/VBN
from/IN
the/DT
protein/NN
data/NNS
bank/NN
(/(
PDB/NN
ID/NN
:/:
2XCT/NN
)/)
./.
====================
The/DT
3D/NN
crystal/JJ
structure/NN
of/IN
this/DT
protein/NN
had/VBD
a/DT
resolution/NN
of/IN
3.35Å/CD
,/,
and/CC
it/PRP
is/VBZ
available/JJ
in/IN
conjugation/NN
with/IN
small/JJ
molecules/NNS
,/,
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1/NN
,/,
4-dihydroquinoline-3-carboxylic/JJ
acid/NN
(/(
CPF/NN
)/)
and/CC
stabilized/VBD
by/IN
manganese/JJ
(/(
II/CD
)/)
ions/NNS
./.
====================
The/DT
topoisomerase-II/NN
DNA/NN
gyrase/NN
enzyme/NN
is/VBZ
composed/VBN
of/IN
two/CD
subunits/NNS
;/:
one/CD
is/VBZ
the/DT
DNA/NN
gyrase/NN
subunit-A/NN
and/CC
another/DT
one/CD
is/VBZ
the/DT
DNA/NN
gyrase/NN
subunit-B/NN
./.
====================
The/DT
3D/NN
structure/NN
consists/VBZ
of/IN
four/CD
chains/NNS
B/NN
,/,
D/NN
,/,
S/NN
,/,
and/CC
U/NNP
with/IN
a/DT
size/NN
of/IN
692/CD
amino/NN
acids/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Topoisomerase-II/NN
DNA/NN
gyrase/NN
structural/JJ
assessment/NN
====================
To/TO
carry/VB
out/RP
molecular/JJ
interaction/NN
studies/NNS
,/,
the/DT
topoisomerase-II/NN
DNA/NN
gyrase/NN
enzyme/NN
of/IN
S./NNP
aureus/FW
structure/NN
was/VBD
evaluated/VBN
for/IN
its/PRP$
three-dimensional/JJ
structural/JJ
properties/NNS
./.
====================
The/DT
stereochemical/JJ
properties/NNS
of/IN
the/DT
DNA/NN
gyrase/NN
structure/NN
were/VBD
analyzed/VBN
via/IN
Ramachandran/NN
plot/NN
./.
====================
The/DT
Ramachandran/NN
plots/NNS
were/VBD
used/VBN
to/TO
assess/VB
dihedral/JJ
angles/NNS
and/CC
a/DT
number/NN
of/IN
amino/NN
acid/NN
residues/NNS
in/IN
favored/JJ
and/CC
disfavoured/VBD
regions/NNS
./.
====================
The/DT
Ramachandran/NN
plot/NN
for/IN
topoisomerase-II/NN
DNA/NN
gyrase/NN
showed/VBD
that/IN
most/JJS
of/IN
the/DT
residues/NNS
of/IN
the/DT
crystal/JJ
structure/NN
are/VBP
in/IN
the/DT
favored/JJ
and/CC
allowed/VBD
regions/NNS
and/CC
a/DT
minimal/JJ
percentage/NN
(/(
4.8/CD
%/NN
)/)
falls/VBZ
in/IN
the/DT
outlier/NN
region/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
The/DT
Verify3D/JJ
web/NN
interface/NN
confirmed/VBD
the/DT
good/JJ
quality/NN
of/IN
the/DT
DNA/NN
gyrase/NN
protein/NN
structure/NN
showing/VBG
that/IN
more/RBR
than/IN
80/CD
%/NN
of/IN
the/DT
amino/NN
acids/NNS
of/IN
the/DT
structure/NN
consist/VBP
of/IN
3D-1D/NN
profiles/NNS
./.
====================
Furthermore/RB
,/,
X-ray/NN
diffraction/NN
studies/NNS
showed/VBD
that/IN
the/DT
crystal/JJ
structure/NN
has/VBZ
a/DT
very/RB
low/JJ
percentage/NN
(/(
9.7/CD
%/NN
)/)
of/IN
side/JJ
chain/NN
outliers/NNS
indicating/VBG
that/IN
the/DT
DNA/NN
gyrase/NN
structure/NN
experimental/JJ
values/NNS
lie/VBP
within/IN
the/DT
range/NN
of/IN
scores/NNS
of/IN
the/DT
native/JJ
protein/NN
structure/NN
of/IN
a/DT
similar/JJ
size/NN
./.
====================
The/DT
structural/JJ
assessments/NNS
carried/VBD
out/RP
with/IN
the/DT
tools/NNS
mentioned/JJ
confirmed/VBD
the/DT
good/JJ
quality/NN
structure/NN
of/IN
the/DT
DNA/NN
gyrase/NN
enzyme/NN
and/CC
could/MD
be/VB
further/RBR
used/VBN
for/IN
molecular/JJ
studies/NNS
./.
====================
Binding/NN
studies/NNS
of/IN
FQs/NN
compounds/NNS
using/VBG
molecular/JJ
docking/NN
====================
Molecular/JJ
interaction/NN
studies/NNS
of/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
compounds/NNS
with/IN
the/DT
target/NN
antibacterial/JJ
protein/NN
(/(
DNA/NN
gyrase/NN
enzyme/NN
of/IN
S./NNP
aureus/FW
)/)
were/VBD
performed/VBN
./.
====================
The/DT
WHATIF/NN
server/RB
protein/NN
preparation/NN
wizard/IN
was/VBD
employed/VBN
to/TO
prepare/VB
the/DT
DNA/NN
gyrase/NN
enzyme/NN
./.
====================
The/DT
prepared/VBN
DNA/NN
gyrase/NN
structure/NN
was/VBD
docked/VBN
with/IN
ciprofloxacin/NN
,/,
ofloxacin/IN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
using/VBG
the/DT
HEX/NN
8.0/CD
molecular/JJ
docking/NN
software/RB
to/TO
obtain/VB
the/DT
best/JJS
possible/JJ
native/JJ
conformation/NN
of/IN
the/DT
protein-ligand/NN
docked/VBD
complex/NN
./.
====================
The/DT
input/NN
parameters/NNS
for/IN
the/DT
molecular/JJ
docking/NN
were/VBD
the/DT
receptor/NN
DNA/NN
gyrase/NN
structure/NN
PDB/NN
coordinate/JJ
files/NNS
and/CC
the/DT
ligand/NN
files/NNS
for/IN
the/DT
ciprofloxacin/NN
,/,
ofloxacin/IN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
compounds/NNS
with/IN
their/PRP$
set/NN
parameters/NNS
./.
====================
On/IN
the/DT
basis/NN
of/IN
the/DT
shape/NN
and/CC
electrostatics/NNS
parameters/NNS
,/,
the/DT
total/JJ
energy/NN
of/IN
interactions/NNS
conformations/NNS
was/VBD
determined/VBN
and/CC
the/DT
resulting/VBG
final/JJ
search/NN
was/VBD
set/NN
to/TO
25/CD
(/(
n/NN
=/JJ
25/CD
)/)
conformations/NNS
./.
====================
The/DT
range/NN
of/IN
the/DT
molecular/JJ
interaction/NN
angular/JJ
search/VBP
was/VBD
confined/VBN
by/IN
selecting/VBG
the/DT
interface/NN
amino/NN
acid/NN
residues/NNS
of/IN
the/DT
DNA/NN
gyrase/NN
enzyme/NN
structure/NN
with/IN
an/DT
angle/JJ
range/NN
of/IN
45°/CD
./.
====================
The/DT
grid/JJ
conformation/NN
box/NN
was/VBD
placed/VBN
on/IN
the/DT
interacting/VBG
sites/NNS
of/IN
the/DT
DNA/NN
gyrase/NN
enzyme/NN
structure/NN
,/,
which/WDT
provides/VBZ
space/NN
for/IN
compound/NN
rotation/NN
and/CC
translations/NNS
./.
====================
The/DT
other/JJ
interaction/NN
parameters/NNS
of/IN
interaction/NN
were/VBD
set/NN
to/TO
the/DT
default/NN
values/NNS
as/IN
given/VBN
in/IN
the/DT
molecular/JJ
docking/NN
suite/JJ
./.
====================
The/DT
molecular/JJ
docking/NN
study/NN
showed/VBD
that/IN
the/DT
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
compounds/NNS
have/VBP
binding/VBG
scores/VBZ
of/IN
−28.88/CD
,/,
−38.52/CD
,/,
−32.92/CD
,/,
and/CC
−34.56/CD
kJ/mol/NN
respectively/RB
./.
====================
Among/IN
all/DT
four/CD
FQs/NNS
compounds/NNS
,/,
the/DT
ofloxacin/NN
compound/NN
has/VBZ
the/DT
highest/JJS
binding/NN
score/VBP
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
The/DT
ofloxacin/NN
compound/NN
was/VBD
found/VBN
to/TO
interact/VB
strongly/RB
with/IN
the/DT
DNA/NN
gyrase/NN
structure/NN
residues/NNS
at/IN
ASN/NN
1013/CD
,/,
VAL/NN
606/CD
,/,
VAL/NN
537/CD
,/,
ALA/NN
1378/CD
,/,
ILE/NN
503/CD
,/,
LEU/NN
1448/CD
,/,
LEU/NN
418/CD
,/,
and/CC
TYR/NN
538/CD
(/(
Table/JJ
1/CD
,/,
Figs/NNS
./.
====================
4/CD
,/,
5/CD
)/)
./.
====================
These/DT
molecular/JJ
docking/NN
simulation/NN
studies/NNS
suggest/VBP
that/IN
the/DT
ofloxacin/NN
can/MD
be/VB
considered/VBN
as/IN
a/DT
potential/JJ
DNA/NN
gyrase/NN
enzyme/NN
inhibitor/NN
to/TO
be/VB
used/VBN
as/IN
an/DT
antibacterial/JJ
drug/NN
./.
====================
Furthermore/RB
,/,
these/DT
four/CD
compounds/NNS
were/VBD
evaluated/VBN
for/IN
their/PRP$
pharmacological/JJ
properties/NNS
./.
====================
Pharmacological/JJ
analysis/NN
of/IN
FQs/NN
compounds/NNS
====================
Pharmacological/JJ
analyses/NNS
of/IN
the/DT
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
compounds/NNS
based/VBN
on/IN
Lipinski/NN
’/CD
s/NNS
rule/NN
of/IN
five/CD
were/VBD
also/RB
performed/VBN
./.
====================
Lipinski/NN
’/CD
s/NNS
rule/NN
of/IN
five/CD
evaluates/VBZ
the/DT
drug-likeness/JJ
of/IN
a/DT
chemical/JJ
compound/NN
and/CC
determines/VBZ
if/IN
a/DT
compound/NN
with/IN
certain/JJ
pharmacological/JJ
characteristics/NNS
would/MD
be/VB
a/DT
possible/JJ
orally/RB
active/JJ
drug/NN
in/IN
humans/NNS
./.
====================
Drug/NN
molecules/NNS
should/MD
be/VB
hydrophobic/JJ
enough/IN
to/TO
last/JJ
for/IN
the/DT
needed/VBN
time/NN
in/IN
the/DT
body/NN
and/CC
not/RB
easily/RB
excreted/VBN
,/,
as/IN
this/DT
will/MD
enhance/VB
the/DT
bioactivity/NN
efficiency/NN
in/IN
the/DT
body/NN
./.
====================
It/PRP
is/VBZ
a/DT
good/JJ
approach/NN
for/IN
drug/NN
lead/VBP
design/NN
,/,
especially/RB
for/IN
hydrophobicity/NN
and/CC
oral/JJ
bioavailability/NN
prediction/NN
./.
====================
Lipinski/NNP
’/NNP
s/NNS
rule/JJ
of/IN
five/CD
consists/VBZ
of/IN
the/DT
following/VBG
predictions/NNS
:/:
molecular/JJ
weight/NN
is/VBZ
from/IN
160/CD
to/TO
500/CD
Da/NN
,/,
octanol-water/RB
partition/NN
coefficient/JJ
(/(
log/NN
P/NN
)/)
is/VBZ
between/IN
−0.4/CD
and/CC
+5.6/CD
,/,
molar/JJ
refractivity/NN
is/VBZ
from/IN
40/CD
to/TO
130/CD
cm3/NN
,/,
hydrogen/NN
donor/NN
is/VBZ
less/RBR
than/IN
5/CD
atoms/NNS
,/,
hydrogen/NN
acceptor/NN
is/VBZ
less/RBR
than/IN
10/CD
atoms/NNS
,/,
and/CC
topological/JJ
polar/JJ
surface/NN
area/NN
is/VBZ
not/RB
more/RBR
than/IN
140/CD
Å/NNP
./.
====================
The/DT
Molinspiration/NN
software/JJ
was/VBD
employed/VBN
to/TO
study/VB
Lipinski/NN
’/CD
s/NNS
rules/NNS
for/IN
the/DT
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
./.
====================
It/PRP
was/VBD
found/VBN
that/IN
all/DT
the/DT
four/CD
FQs/NNS
compounds/NNS
do/VBP
not/RB
violate/VB
any/DT
part/NN
of/IN
Lipinski/NN
’/CD
s/NNS
rule/NN
of/IN
five/CD
and/CC
also/RB
followed/VBN
all/DT
the/DT
requisite/JJ
properties/NNS
needed/VBD
for/IN
a/DT
potent/JJ
drug/NN
./.
====================
The/DT
results/NNS
also/RB
indicate/VBP
that/IN
compounds/NNS
are/VBP
hydrophobic/JJ
as/IN
they/PRP
have/VBP
a/DT
low/JJ
solubility/NN
in/IN
water/NN
./.
====================
With/IN
their/PRP$
good/JJ
hydrophobicity/NN
,/,
it/PRP
can/MD
be/VB
concluded/VBN
that/IN
these/DT
compounds/NNS
(/(
ciprofloxacin/NN
,/,
ofloxacin/IN
,/,
lomefloxacin/NN
,/,
norfloxacin/NN
)/)
will/MD
be/VB
able/JJ
to/TO
circulate/VB
long/JJ
enough/IN
for/IN
the/DT
optimal/JJ
duration/NN
and/CC
will/MD
be/VB
excreted/VBN
conveniently/RB
./.
====================
This/DT
will/MD
enhance/VB
their/PRP$
interaction/NN
duration/NN
with/IN
the/DT
target/NN
protein/NN
DNA/NN
gyrase/NN
enzyme/NN
and/CC
consequently/RB
,/,
result/NN
in/IN
an/DT
efficient/JJ
inhibition/NN
of/IN
the/DT
target/NN
antibacterial/JJ
protein/NN
./.
====================
The/DT
other/JJ
pharmacological/JJ
parameters/NNS
analyzed/VBD
were/VBD
the/DT
ADME/NN
properties/NNS
of/IN
the/DT
FQ/NN
compounds/NNS
./.
====================
The/DT
adsorption/NN
properties/NNS
of/IN
all/DT
four/CD
compounds/NNS
were/VBD
analyzed/VBN
./.
====================
These/DT
properties/NNS
included/VBD
the/DT
water/NN
solubility/NN
,/,
Caco2/NN
permeability/NN
,/,
intestinal/JJ
absorption/NN
in/IN
humans/NNS
,/,
skin/NN
permeability/NN
and/CC
P-glycoprotein/NN
inhibition/NN
./.
====================
All/DT
four/CD
compounds/NNS
(/(
ciprofloxacin/NN
,/,
norfloxacin/NN
,/,
ofloxacin/IN
,/,
and/CC
lomefloxacin/NN
)/)
were/VBD
found/VBN
to/TO
have/VB
high/JJ
water/NN
solubility/NN
with/IN
values/NNS
of/IN
−2.55/CD
,/,
−3.03/CD
,/,
−3.35/CD
,/,
and/CC
−3.31/CD
,/,
respectively/RB
./.
====================
These/DT
values/NNS
represent/JJ
the/DT
high/JJ
water/NN
solubility/NN
of/IN
FQ/NN
compounds/NNS
at/IN
25°C/NN
,/,
defined/VBN
on/IN
the/DT
basis/NN
of/IN
a/DT
database/NN
of/IN
more/RBR
than/IN
1,700/CD
drug/NN
molecules/NNS
./.
====================
The/DT
Caco2/NN
permeability/NN
analysis/NN
showed/VBD
that/IN
ofloxacin/NN
possesses/VBZ
a/DT
higher/JJR
permeability/NN
(/(
with/IN
a/DT
score/RB
of/IN
1.402/CD
)/)
than/IN
other/JJ
FQs/JJ
compounds/NNS
studied/VBD
./.
====================
Caco2/NN
permeability/NN
is/VBZ
an/DT
important/JJ
property/NN
since/IN
these/DT
monolayers/NNS
of/IN
cells/NNS
are/VBP
widely/RB
used/VBN
in/IN
the/DT
study/NN
of/IN
the/DT
oral/JJ
administration/NN
of/IN
compounds/NNS
during/IN
the/DT
in/FW
vitro/FW
human/JJ
model/NN
studies/NNS
./.
====================
Another/DT
important/JJ
consideration/NN
in/IN
the/DT
absorption/NN
of/IN
the/DT
drugs/NNS
is/VBZ
intestinal/JJ
absorption/NN
during/IN
oral/JJ
administration/NN
./.
====================
Ofloxacin/NN
was/VBD
found/VBN
to/TO
have/VB
a/DT
high/JJ
absorption/NN
in/IN
the/DT
intestine/NN
with/IN
a/DT
high/JJ
score/RB
of/IN
96.964/CD
,/,
as/IN
shown/VBN
in/IN
Table/JJ
2/CD
./.
====================
After/IN
that/DT
,/,
the/DT
skin/NN
permeability/NN
of/IN
the/DT
compounds/NNS
was/VBD
studied/VBN
,/,
as/IN
it/PRP
is/VBZ
an/DT
important/JJ
parameter/NN
for/IN
the/DT
transdermal/JJ
delivery/NN
of/IN
the/DT
drugs/NNS
./.
====================
The/DT
analysis/NN
revealed/VBD
that/IN
ofloxacin/NN
has/VBZ
a/DT
good/JJ
skin/NN
permeability/NN
in/IN
comparison/NN
to/TO
the/DT
other/JJ
compounds/NNS
,/,
which/WDT
possesses/VBZ
low/JJ
permeability/NN
values/NNS
./.
====================
Moreover/RB
,/,
all/DT
four/CD
compounds/NNS
were/VBD
found/VBN
to/TO
possess/VB
the/DT
P-glycoprotein/NN
substrate/NN
characteristics/NNS
with/IN
no/DT
inhibition/NN
of/IN
P-glycoprotein/NN
./.
====================
These/DT
adsorption/NN
based/VBN
pharmacological/JJ
studies/NNS
showed/VBD
that/IN
all/DT
four/CD
compounds/NNS
possess/VBP
good/JJ
adsorption/NN
properties/NNS
,/,
and/CC
ofloxacin/NN
possesses/VBZ
high-quality/JJ
factors/NNS
as/IN
a/DT
potential/JJ
antibacterial/JJ
drug/NN
./.
====================
After/IN
that/DT
,/,
the/DT
pharmacological/JJ
properties/NNS
,/,
including/VBG
the/DT
distribution/NN
of/IN
drugs/NNS
were/VBD
studied/VBN
,/,
which/WDT
include/VBP
the/DT
volume/NN
of/IN
distribution/NN
(/(
VDss/NNP
)/)
,/,
fraction/NN
unbound/JJ
in/IN
human/JJ
,/,
blood-brain/VBP
barrier/RBR
(/(
BBB/NN
)/)
permeability/NN
,/,
and/CC
central/JJ
nervous/JJ
system/NN
(/(
CNS/NN
)/)
permeability/NN
./.
====================
The/DT
VDss/NN
reflects/VBZ
the/DT
drug/NN
volume/NN
needed/VBD
so/RB
that/IN
the/DT
dose/NN
of/IN
the/DT
drug/NN
would/MD
distribute/VB
uniformly/RB
to/TO
provide/VB
a/DT
similar/JJ
degree/NN
of/IN
concentration/NN
in/IN
the/DT
blood/NN
./.
====================
Among/IN
the/DT
compounds/NNS
,/,
ciprofloxacin/NN
and/CC
ofloxacin/NN
showed/VBD
good/JJ
values/NNS
for/IN
uniform/JJ
distribution/NN
./.
====================
The/DT
fraction/NN
of/IN
drug/NN
unbound/JJ
in/IN
the/DT
human/JJ
analysis/NN
showed/VBD
that/IN
out/RB
of/IN
all/DT
the/DT
FQ/NN
compounds/NNS
,/,
ofloxacin/IN
has/VBZ
a/DT
minimal/JJ
unbound/JJ
fraction/NN
with/IN
a/DT
value/NN
of/IN
0.375/CD
(/(
Table/JJ
3/CD
)/)
./.
====================
This/DT
suggests/VBZ
that/IN
all/DT
four/CD
compounds/NNS
have/VBP
good/VBN
distribution/NN
level/NN
pharmacological/JJ
properties/NNS
with/IN
very/RB
low/JJ
BBB/NN
permeability/NN
and/CC
CNS/NN
permeability/NN
./.
====================
Next/RB
,/,
the/DT
metabolism/NN
pharmacological/JJ
parameters/NNS
of/IN
four/CD
compounds/NNS
were/VBD
studied/VBN
./.
====================
All/DT
four/CD
compounds/NNS
were/VBD
not/RB
found/VBN
to/TO
inhibit/VB
the/DT
cytochrome/NN
P450/NN
and/CC
its/PRP$
different/JJ
isoforms/NNS
(/(
CYP1A2/NN
,/,
CYP2C19/NN
,/,
CYP2C9/NN
,/,
CYP2D6/NN
,/,
and/CC
CYP3A4/NN
)/)
./.
====================
This/DT
suggests/VBZ
that/IN
the/DT
noninhibition/NN
of/IN
cytochrome/NN
P450/NN
will/MD
help/VB
in/IN
the/DT
metabolism/NN
of/IN
these/DT
compounds/NNS
(/(
Table/JJ
4/CD
)/)
./.
====================
However/RB
,/,
none/NN
of/IN
the/DT
compounds/NNS
were/VBD
found/VBN
as/IN
a/DT
substrate/NN
of/IN
cytochrome/NN
P450/NN
./.
====================
All/DT
four/CD
drugs/NNS
(/(
ciprofloxacin/NN
,/,
norfloxacin/NN
,/,
ofloxacin/IN
,/,
and/CC
lomefloxacin/NN
)/)
were/VBD
also/RB
found/VBD
to/TO
possess/VB
the/DT
optimal/JJ
total/JJ
clearance/NN
values/NNS
0.483/CD
,/,
0.361/CD
,/,
0.323/CD
,/,
and/CC
0.188/CD
mL/min/kg/NN
respectively/RB
(/(
Table/JJ
5/CD
)/)
./.
====================
The/DT
total/JJ
clearance/NN
reflects/VBZ
the/DT
hepatic/JJ
clearance/NN
and/CC
renal/JJ
clearance/NN
and/CC
indicates/VBZ
the/DT
requisite/JJ
bioavailability/NN
property/NN
for/IN
uniform/JJ
dosing/NN
concentrations/NNS
./.
====================
We/PRP
found/VBD
that/IN
all/DT
four/CD
compounds/NNS
possess/VBP
no/DT
violations/NNS
of/IN
the/DT
Lipinski/NN
rule/JJ
of/IN
five/CD
and/CC
other/JJ
algorithms/NNS
and/CC
high/JJ
drug/NN
likelines/NNS
with/IN
a/DT
large/JJ
number/NN
of/IN
approved/JJ
drugs/NNS
./.
====================
Pharmacokinetic/JJ
and/CC
toxicity/NN
analysis/NN
====================
The/DT
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
compounds/NNS
were/VBD
further/RB
studied/VBN
for/IN
their/PRP$
pharmacokinetic/JJ
properties/NNS
and/CC
toxicity/NN
using/VBG
the/DT
pkCSM/NN
and/CC
FAF-Drug/NN
approaches/NNS
./.
====================
First/RB
,/,
the/DT
Ames/NNS
toxicity/NN
analysis/NN
of/IN
the/DT
compounds/NNS
was/VBD
performed/VBN
,/,
and/CC
it/PRP
was/VBD
seen/VBN
that/IN
ofloxacin/NN
and/CC
norfloxacin/NN
do/VBP
not/RB
show/VB
Ames/NNS
toxicity/NN
./.
====================
Since/IN
Ames/NNS
test/NN
positive/JJ
compounds/NNS
may/MD
be/VB
mutagenic/JJ
and/CC
may/MD
lead/VB
to/TO
cancer/NN
./.
====================
Moreover/RB
,/,
all/DT
four/CD
compounds/NNS
were/VBD
not/RB
found/VBN
to/TO
inhibit/VB
the/DT
hERG-1/NN
(/(
human/JJ
ether/NN
a/DT
go-go/JJ
gene/NN
)/)
and/CC
hERG-2/NN
./.
====================
The/DT
inhibition/NN
of/IN
these/DT
regulatory/JJ
potassium/NN
channels/NNS
leads/VBZ
to/TO
the/DT
development/NN
of/IN
long/JJ
QT/NN
syndrome/NN
to/TO
fatal/JJ
ventricular/JJ
arrhythmia/NN
./.
====================
Based/VBN
on/IN
the/DT
hydrophobicity/NN
of/IN
the/DT
designed/VBN
compounds/NNS
,/,
the/DT
oral/JJ
bioavailability/NN
was/VBD
also/RB
calculated/VBN
using/VBG
the/DT
FAF-Drugs/NNS
and/CC
pkCSM/NN
software/JJ
./.
====================
The/DT
FAF-Drugs/NNS
prediction/NN
showed/VBD
that/IN
all/DT
four/CD
compounds/NNS
have/VBP
a/DT
good/JJ
oral/JJ
bioavailability/NN
based/VBN
on/IN
Veber/NN
’/CD
s/NNS
and/CC
Egan/NN
’/CD
s/NNS
rules/NNS
./.
====================
Next/RB
,/,
using/VBG
the/DT
pkCSM/NN
software/JJ
,/,
the/DT
maximum/NN
recommended/VBN
tolerated/VBN
doses/NNS
were/VBD
calculated/VBN
for/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
./.
====================
All/DT
four/CD
compounds/NNS
were/VBD
found/VBN
to/TO
have/VB
high/JJ
oral/JJ
rat/NN
acute/JJ
toxicity/NN
values/NNS
(/(
2.311/CD
,/,
2.22/CD
,/,
2.237/CD
,/,
and/CC
2.216/CD
log/NN
mg/kg/day/NN
,/,
respectively/RB
)/)
./.
====================
This/DT
indicates/VBZ
the/DT
high/JJ
tolerance/NN
of/IN
compounds/NNS
with/IN
recommended/VBN
tolerated/VBN
doses/NNS
(/(
Table/JJ
6/CD
)/)
./.
====================
The/DT
results/NNS
were/VBD
based/VBN
on/IN
the/DT
maximum/NN
recommended/VBN
starting/VBG
dose/NN
in/IN
the/DT
phase-1/NN
clinical/JJ
trials/NNS
,/,
based/VBN
on/IN
the/DT
experimental/JJ
data/NNS
of/IN
1,222/NN
human/JJ
clinical/JJ
trials/NNS
./.
====================
Importantly/RB
,/,
these/DT
compounds/NNS
were/VBD
also/RB
not/RB
found/VBN
to/TO
cause/VB
any/DT
skin/NN
sensations/NNS
./.
====================
Lastly/RB
,/,
we/PRP
analyzed/VBD
the/DT
antibacterial/JJ
characteristics/NNS
of/IN
the/DT
compounds/NNS
against/IN
Tetrahymena/NN
pyriformis/NN
./.
====================
We/PRP
found/VBD
that/IN
all/DT
the/DT
analyzed/VBN
compounds/NNS
(/(
ciprofloxacin/NN
,/,
ofloxacin/IN
,/,
lomefloxacin/NN
and/CC
norfloxacin/NN
)/)
have/VBP
a/DT
high/JJ
toxicity/NN
against/IN
the/DT
protozoa/NN
with/IN
a/DT
high/JJ
IGC50/NN
(/(
concentration/NN
required/VBN
to/TO
inhibit/VB
the/DT
50/CD
%/NN
growth/NN
in/IN
log/NN
μg/L/NN
)/)
score/RB
:/:
0.344/CD
,/,
0.292/CD
,/,
0.286/CD
,/,
and/CC
0.29/CD
μg/L/NN
respectively/RB
./.
====================
Moreover/RB
,/,
the/DT
Minnow/NN
toxicity/NN
values/NNS
for/IN
the/DT
compounds/NNS
were/VBD
calculated/VBN
and/CC
showed/VBD
that/IN
ciprofloxacin/NN
,/,
ofloxacin/IN
,/,
lomefloxacin/NN
,/,
norfloxacin/NN
have/VBP
values/NNS
of/IN
1.64/CD
,/,
1.3/CD
,/,
1.47/CD
,/,
and/CC
1.21/CD
,/,
respectively/RB
./.
====================
These/DT
results/NNS
concluded/VBD
that/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
have/VBP
good/VBN
bioactivity/NN
with/IN
significant/JJ
pharmacological/JJ
properties/NNS
./.
====================
In/IN
conclusion/NN
,/,
among/IN
the/DT
four/CD
tested/VBN
FQs/NNS
(/(
ciprofloxacin/NN
,/,
ofloxacin/IN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
)/)
,/,
ofloxacin/IN
exhibited/VBD
a/DT
high/JJ
antibacterial/JJ
activity/NN
by/IN
in/FW
silico/JJ
assays/NNS
with/IN
high/JJ
binding/NN
docking/NN
score/RB
of/IN
−38.52/NN
kJ/mol/NN
to/TO
topoisomerase-II/NN
DNA/NN
gyrase/NN
(/(
a/DT
well-known/JJ
antibacterial/JJ
target/NN
protein/NN
)/)
./.
====================
All/DT
four/CD
analyzed/VBD
FQ/NN
compounds/NNS
meet/VBP
Lipinski/NN
’/CD
s/NNS
rule/NN
of/IN
five/CD
and/CC
show/VBP
drug-likeliness/IN
./.
====================
Based/VBN
on/IN
our/PRP$
results/NNS
,/,
they/PRP
also/RB
have/VBP
a/DT
high/JJ
passive/JJ
absorption/NN
and/CC
good/JJ
oral/JJ
bioavailability/NN
based/VBN
on/IN
Veber/NN
’/CD
s/NNS
and/CC
Egan/NN
’/CD
s/NNS
rules/NNS
and/CC
is/VBZ
not/RB
toxic/JJ
to/TO
humans/NNS
./.
====================
The/DT
pharmacological/JJ
and/CC
pharmacokinetic/JJ
analysis/NN
of/IN
the/DT
compounds/NNS
showed/VBD
that/IN
all/DT
four/CD
compounds/NNS
have/VBP
good/VBN
pharmacological/JJ
properties/NNS
./.
====================
Moreover/RB
,/,
ofloxacin/NN
was/VBD
found/VBN
to/TO
possess/VB
high/JJ
IGC50/NN
value/NN
of/IN
0.286/CD
μg/L/NN
against/IN
the/DT
T./FW
pyriformis/NN
protozoa/NN
./.
====================
Ofloxacin/NN
and/CC
norfloxacin/NN
compounds/NNS
were/VBD
tested/VBN
to/TO
be/VB
negative/JJ
for/IN
the/DT
Ames/NNS
toxicity/NN
test/NN
,/,
showing/VBG
the/DT
non-carcinogenic/JJ
character/NN
of/IN
the/DT
compounds/NNS
./.
====================
In/IN
particular/JJ
,/,
all/DT
four/CD
compounds/NNS
exhibit/VBP
marked/JJ
activity/NN
against/IN
microorganisms/NNS
,/,
because/IN
they/PRP
strongly/RB
interact/VB
with/IN
the/DT
active/JJ
sites/NNS
of/IN
topoisomerase/NN
II/CD
DNA/NN
gyrase/NN
enzymes/NNS
and/CC
are/VBP
supported/VBN
by/IN
the/DT
optimal/JJ
pharmacological/JJ
properties/NNS
./.
====================
Diagram/NN
depicting/VBG
the/DT
three-/NN
dimensional/JJ
structure/NN
of/IN
topoisomerase-II/NN
DNA/NN
gyrase/NN
enzyme/NN
in/IN
newcartoon/JJ
view/NN
./.
====================
The/DT
structure/NN
consisted/VBD
of/IN
four/CD
chains/NNS
shown/VBN
in/IN
the/DT
different/JJ
colors/NNS
(/(
yellow/RB
,/,
blue/JJ
,/,
green/VBN
,/,
and/CC
red/JJ
colors/NNS
)/)
./.
====================
Ramachandran/NN
plot/NN
of/IN
DNA/NN
gyrase/NN
structure/NN
./.
====================
The/DT
plot/NN
is/VBZ
showing/VBG
the/DT
major/JJ
region/NN
of/IN
the/DT
structure/NN
lies/VBZ
within/IN
the/DT
favored/JJ
and/CC
allowed/VBD
region/NN
./.
====================
Depiction/NN
of/IN
molecular/JJ
docking/NN
interaction/NN
of/IN
ciprofloxacin/NN
,/,
ofloxacin/IN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
(/(
all/DT
four/CD
in/IN
different/JJ
color/JJ
views/VBZ
)/)
with/IN
DNA/NN
gyrase/NN
enzyme/NN
protein/NN
(/(
newcartoon/RB
ribbon/NN
view/NN
)/)
to/TO
its/PRP$
binding/NN
grove/JJ
./.
====================
The/DT
surface/NN
view/NN
of/IN
interactions/NNS
of/IN
norfloxacin/NN
and/CC
ciprofloxacin/NN
to/TO
DNA/NN
gyrase/NN
enzyme/NN
protein/NN
binding/NN
groove/NN
./.
====================
(/(
A/NN
)/)
Norfloxacin/NN
(/(
green/CD
)/)
with/IN
DNA/NN
gyrase/NN
enzyme/NN
(/(
red/JJ
)/)
./.
====================
(/(
B/NN
)/)
Ciprofloxacin/NN
(/(
yellow/RB
color/JJ
)/)
with/IN
DNA/NN
gyrase/NN
enzyme/NN
(/(
black/JJ
)/)
./.
====================
The/DT
surface/NN
view/NN
of/IN
molecular/JJ
interactions/NNS
of/IN
ofloxacin/NN
and/CC
lomefloxacin/NN
to/TO
DNA/NN
gyrase/NN
enzyme/NN
protein/NN
binding/NN
groove/NN
./.
====================
(/(
A/NN
)/)
Ofloxacin/NN
(/(
orange/NN
)/)
with/IN
DNA/NN
gyrase/NN
enzyme/NN
(/(
grey/PRP
)/)
./.
====================
(/(
B/NN
)/)
Lomefloxacin/NN
(/(
cyan/JJ
)/)
with/IN
DNA/NN
gyrase/NN
enzyme/NN
(/(
blue/JJ
)/)
./.
====================
Molecular/JJ
binding/NN
free/JJ
energy/NN
scores/VBZ
of/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
compounds/NNS
with/IN
the/DT
receptor/NN
DNA/NN
gyrase/NN
enzyme/NN
,/,
using/VBG
HEX/NN
8.0/CD
molecular/JJ
docking/NN
suite/JJ
====================
Absorption/NN
properties/NNS
analysis/NN
of/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
compounds/NNS
====================
Pharmacological/JJ
properties/NNS
including/VBG
the/DT
distribution/NN
of/IN
drugs/NNS
analysis/NN
for/IN
the/DT
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
====================
Metabolism/NN
properties/NNS
analysis/NN
of/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
====================
Excretion/NN
properties/NNS
analysis/NN
of/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
====================
Toxicity/NN
properties/NNS
analysis/NN
of/IN
ciprofloxacin/NN
,/,
ofloxacin/NN
,/,
lomefloxacin/NN
,/,
and/CC
norfloxacin/NN
compounds/NNS
====================
